Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:BRNS NASDAQ:COEP NASDAQ:FBLG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$2.77-1.1%$2.86$2.00▼$5.00$11.61M2.1371,339 shs80,225 shsBRNSBarinthus Biotherapeutics$1.50-2.1%$0.96$0.64▼$2.92$60.41M-0.8325,553 shs400,864 shsCOEPCoeptis Therapeutics$10.68-5.2%$8.93$2.31▼$13.70$37.53M-0.63121,723 shs39,027 shsFBLGFibroBiologics$0.67-2.7%$0.77$0.58▼$5.54$26.64M-0.78314,230 shs411,673 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos0.00%-7.05%+1.67%+0.73%-24.01%BRNSBarinthus Biotherapeutics0.00%+46.11%+67.52%+105.18%-0.17%COEPCoeptis Therapeutics0.00%+13.48%+38.34%+6.80%+83.13%FBLGFibroBiologics0.00%+6.69%-6.49%-43.58%-87.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.8416 of 5 stars0.05.00.00.00.01.70.6BRNSBarinthus Biotherapeutics3.3695 of 5 stars3.55.00.00.02.30.81.3COEPCoeptis Therapeutics0.2087 of 5 stars0.03.00.00.00.01.70.0FBLGFibroBiologics3.2558 of 5 stars3.65.00.00.01.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/ABRNSBarinthus Biotherapeutics 3.00Buy$6.25317.33% UpsideCOEPCoeptis Therapeutics 0.00N/AN/AN/AFBLGFibroBiologics 3.20Buy$13.001,836.25% UpsideCurrent Analyst Ratings BreakdownLatest AIMD, BRNS, FBLG, and COEP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/17/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/15/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$20K580.32N/AN/A$5.51 per share0.50BRNSBarinthus Biotherapeutics$14.97M4.04N/AN/A$3.23 per share0.46COEPCoeptis TherapeuticsN/AN/AN/AN/A$1.61 per shareN/AFBLGFibroBiologicsN/AN/AN/AN/A$0.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$6.45N/A∞N/AN/A-88.07%-48.60%8/4/2025 (Estimated)BRNSBarinthus Biotherapeutics-$61.07M-$1.64N/AN/AN/AN/A-46.43%-38.50%8/6/2025 (Estimated)COEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-282.39%-127.23%N/AFBLGFibroBiologics-$11.16M-$0.21N/AN/AN/AN/A-1,022.04%-117.56%8/6/2025 (Estimated)Latest AIMD, BRNS, FBLG, and COEP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.33N/AN/AN/AN/AN/A8/6/2025Q1 2025FBLGFibroBiologics-$0.11N/AN/AN/AN/AN/A5/14/2025Q1 2025COEPCoeptis TherapeuticsN/A-$1.11N/A-$1.11N/AN/A5/13/2025Q1 2025FBLGFibroBiologics-$0.10-$0.14-$0.04-$0.14N/AN/A5/12/2025Q1 2025AIMDAinosN/A-$1.05N/A-$0.21N/A$0.11 million5/7/2025Q1 2025BRNSBarinthus Biotherapeutics-$0.34-$0.49-$0.15-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/ACOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.842.001.91BRNSBarinthus BiotherapeuticsN/A9.189.18COEPCoeptis Therapeutics0.020.820.82FBLGFibroBiologicsN/A1.141.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ABRNSBarinthus Biotherapeutics25.20%COEPCoeptis Therapeutics13.88%FBLGFibroBiologicsN/AInsider OwnershipCompanyInsider OwnershipAIMDAinos10.39%BRNSBarinthus Biotherapeutics10.70%COEPCoeptis Therapeutics24.25%FBLGFibroBiologics20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos404.19 million3.76 millionNot OptionableBRNSBarinthus Biotherapeutics10740.34 million36.02 millionN/ACOEPCoeptis Therapeutics23.51 million2.66 millionNot OptionableFBLGFibroBiologics1039.68 million31.75 millionN/AAIMD, BRNS, FBLG, and COEP HeadlinesRecent News About These CompaniesHead-To-Head Contrast: Neumora Therapeutics (NASDAQ:NMRA) and FibroBiologics (NASDAQ:FBLG)July 12, 2025 | americanbankingnews.comBrag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJuly 11, 2025 | usatoday.comFibroBiologics to Present at the Advanced Wound Care Summit USAJuly 11, 2025 | globenewswire.comFibroBiologics Inc. (NASDAQ:FBLG) Receives Average Rating of "Buy" from BrokeragesJuly 11, 2025 | americanbankingnews.comFibroBiologics Confirms Ability to Manufacture CybroCell™ for ...July 10, 2025 | finance.yahoo.comFibrobiologics Confirms Ability to Manufacture Cybrocell for Degenerative Disc Disease and Cartilage Repair Programs from Existing Cywc628 Master Cell BankJuly 9, 2025 | marketscreener.comMFibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell BankJuly 9, 2025 | globenewswire.comFibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10July 7, 2025 | finance.yahoo.comFibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10July 7, 2025 | globenewswire.comFibroBiologics, Inc. (FBLG) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comFibroBiologics to Present Company Update and Research Advances at BIO International Convention 2025June 17, 2025 | nasdaq.comFibroBiologics Secures $5M in Equity Purchase AgreementJune 16, 2025 | tipranks.comFibroBiologics Closes Third $5 Million Tranche of $25 Million FinancingJune 16, 2025 | globenewswire.comFibroBiologics to Present at the BIO International Convention 2025June 16, 2025 | globenewswire.comFibroBiologics, Inc. Holds Annual Stockholders MeetingJune 13, 2025 | tipranks.comFibroBiologics Appoints Jason D. Davis as CFOJune 9, 2025 | tipranks.comFibrobiologics, Inc.: FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial OfficerJune 9, 2025 | finanznachrichten.deFibroBiologics announces CFO appointmentJune 9, 2025 | kalkinemedia.comKFibroBiologics, Inc. Appoints Jason D. Davis as Chief Financial Officer to Drive Growth and Clinical DevelopmentJune 9, 2025 | quiverquant.comQFibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial OfficerJune 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, BRNS, FBLG, and COEP Company DescriptionsAinos NASDAQ:AIMD$2.77 -0.03 (-1.07%) As of 07/18/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Barinthus Biotherapeutics NASDAQ:BRNS$1.50 -0.03 (-2.12%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$1.47 -0.03 (-1.84%) As of 07/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Coeptis Therapeutics NASDAQ:COEP$10.68 -0.58 (-5.15%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$10.99 +0.31 (+2.90%) As of 07/18/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.FibroBiologics NASDAQ:FBLG$0.67 -0.02 (-2.70%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.67 0.00 (-0.21%) As of 07/18/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.